Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to identify brain biomarkers and characteristics that predict
individual responses to treatment of major depression with the antidepressant drug sertraline
(tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant.
Our central hypothesis is that brain activity and connections jointly measured with
functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to
predict an individual's response to sertraline treatment.